Targeted therapies interfering with oncogenic driver alterations have achieved great success in chronic myeloid leukaemia (CML) with BCR‐ABL fusions,1 melanoma with BRAF V600E mutations,2 lung cancer with EGFR mutations3 and breast cancer with HER2 amplification.4 This evidence concerns the gene ERBB2 and breast carcinoma.